Preferred Pharmaceuticals Recalls Nature-Throid Tablets Due to CGMP Deviations
Preferred Pharmaceuticals is voluntarily recalling Nature-Throid tablets due to Current Good Manufacturing Practice (CGMP) deviations. The affected repackaged tablets were sold to three physicians in California and Georgia.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation that might cause temporary or medically reversible health consequences. The source text does not report any specific illnesses or injuries, and the hazard is related to manufacturing deviations rather than a high-risk pathogen or structural defect.
Plain-English summary
Preferred Pharmaceuticals, Inc. is voluntarily recalling Nature-Throid, 1/2 Grain, 32.5 mg tablets. The recall was initiated on September 2, 2020, and was classified as Class II by the FDA. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.
The affected product consists of 100-count tablets containing Thyroid U.S.P., Liothyronine (T3), and Levothyroxine (T4). The specific lots involved are L2717G (Exp. 12/31/2020), B2618A (Exp. 12/21/2020), and C1419P (Exp. 2/28/2021). The NDC number for the product is 68788-9283-01.
The repackaged tablets were sold to three physicians located in California and Georgia. The recall status is currently terminated as of April 25, 2024. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates.
The recalled product
- Product
- Nature-Throid, 1/2 Grain, 32.5 mg (Thyroid U.S.P. 1/2 gr. (32.5 mg)/Liothyronine (T3) 4.5mcg/Levothyroxine (T4) 19mch, 100-count tablets, Rx Only, Mfg: RLC Labs; Cave Creek, AZ, Preferred Pharmaceuticals, Inc. NDC 68788-9283-01
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Thyroid Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: L2717G
- Exp. Date: 12/31/2020
- Lot #: B2618A
- Exp. Date: 12/21/2020
- Lot #: C1419P
- Exp. Date: 2/28/2021
Distribution
Part of a larger recall action
This product is one of 4 recalled by Preferred Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · cgmp deviations
See all →- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateDrug Recall: APAP 500 mg Phenyl HCl Tablets for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateMigrenol Caplet Drug Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16